Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Contact information


philip.langer@cardiov.ox.ac.uk


ORCID ID https://orcid.org/0009-0007-2648-9739


Division of Cardiovascular Medicine, Level 6 West Wing, John Radcliffe Hospital, University of Oxford, OX3 0AG

Recent Biography

Since completing my PhD, I have joined Prof Robin Choudhury's Group here at the RDM, as part of the wider MRC/BHF Centre of Research Excellence in Advanced Cardiac Therapies (REACT).

We are focused on creating novel immunomodulatory gene therapies to combat fibrosis post-myocardial infarction to create the optimal environment for myocardial regeneration.

During my BSc (Hons) Pharmacology with a Modern Language degree at the University of Manchester and Nagoya University, I developed a strong interest in the delivery of biopharmaceuticals via gene therapy.

Further expanding on this interest, I subsequently completed a PhD at the University of Bristol and University of Washington, within the Ophthalmology Research Group led by Prof Andrew Dick as part of the NIHR Moorfields BRC.

My doctoral research focused on characterising, manipulating, and overcoming the retinal immune response to recombinant adeno-associated virus (rAAV) vectors, and creating a new cutting-edge gene therapy for the treatment of autoimmune uveitis.

Philip M Langer

PhD, BSc (Hons)

Postdoctoral Research Associate

Promoting myocardial regeneration via gene therapy

Research Interests

[under construction]

Recent publications

More publications